For most of the 2010s, vaccines were not considered to be particularly profitable projects for biotech companies to pursue. After all, the nature of the market is that demand is linked to population growth, making it consistently low, which in turn keeps prices and margins down. Now, it looks like the coronavirus pandemic could flip the script and leave vaccine makers flush with cash and broadly profitable, at least in the medium term.
Between its recently approved coronavirus vaccine and its other projects on the verge of commercialization or major milestones, Novavax (NASDAQ: NVAX) is one company that’s on track to enrich investors for the foreseeable future. Over the next couple of years, its revenue reports will start to reflect its soon-to-be tremendous sales volume, and it will continue to innovate with vaccine technologies. But potential buyers may struggle to find an entry point for the stock they are comfortable with, especially if they don’t understand the most important catalysts coming up for the company.